Literature DB >> 21455718

Treatment of generalized dystonia.

Naomi Lubarr1, Susan Bressman.   

Abstract

OPINION STATEMENT: The armamentarium for clinicians treating patients with generalized dystonia, previously restricted to only a few oral medications that often caused intolerable side effects, has been radically expanded in the past decade with the widespread application of deep brain stimulation (DBS). With DBS, patients who in the past would have been restricted to a life of severe motor disability from a young age can now lead lives with only minimal symptoms. Although DBS should therefore be considered as a treatment option for any patient with severe, medically refractory dystonia, important questions remain about patient selection, including what factors predict which patients will benefit from DBS, and when in the course of disease DBS should be performed. Reports show that patients with primary dystonia respond better than those with secondary dystonia, and limb and axial muscles may improve more than cranial dystonia. Some studies also suggest that shorter duration of disease may be associated with better outcomes. However, it is important to note that even among those thought to respond best to DBS, i.e. patients with primary generalized dystonia, there is a subset that will have significant and sustained clinical benefit with oral medications. It is therefore important that adequate trials of oral medications be attempted prior to referral for surgery. On the other hand, once it is clear that medical therapies are not providing significant benefit or are not well tolerated, children with disabling generalized primary dystonia should be referred quickly for DBS. The dramatic clinical improvement that can be seen with DBS can restore normal or near-normal functioning and avoid the physical and emotional costs of an extended period of decreased physical and social functioning. In general, a levodopa trial should always be considered as the first treatment at the time of presentation of any patient with childhood-onset limb dystonia, in order to exclude dopa-responsive dystonia. Once a diagnosis of primary generalized dystonia is established, we typically initiate treatment with trihexyphenidyl, titrating slowly up to a high dose. We then frequently add baclofen as a second agent. If clinical improvement at that point is inadequate and the dystonia is causing significant functional impairment, we then consider referral for DBS.

Entities:  

Year:  2011        PMID: 21455718     DOI: 10.1007/s11940-011-0122-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  63 in total

1.  Preservation of cognitive function in dystonia treated by pallidal stimulation.

Authors:  B Pillon; C Ardouin; K Dujardin; P Vittini; A Pelissolo; O Cottencin; L Vercueil; J-L Houeto; P Krystkowiak; Y Agid; A Destée; P Pollak; M Vidailhet
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

2.  Deep brain stimulation in acute management of status dystonicus.

Authors:  Robert Jech; Martin Bares; Dusan Urgosík; Olga Cerná; Petr Klement; Miriam Adamovicová; Evzen Růzicka; Iva Príhodová; Hana Oslejsková
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 3.  Intrathecal baclofen in the treatment of dystonia.

Authors:  B Ford; P E Greene; E D Louis; S B Bressman; R R Goodman; M F Brin; S Sadiq; S Fahn
Journal:  Adv Neurol       Date:  1998

4.  Pallidal deep-brain stimulation in primary generalized or segmental dystonia.

Authors:  Andreas Kupsch; Reiner Benecke; Jörg Müller; Thomas Trottenberg; Gerd-Helge Schneider; Werner Poewe; Wilhelm Eisner; Alexander Wolters; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger Marie Skogseid; Geir Ketil Roeste; Juliane Vollmer-Haase; Angela Brentrup; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Markus Naumann; Jens Volkmann
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

5.  Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration.

Authors:  Martin Krause; Wolfgang Fogel; Volker Tronnier; Sabine Pohle; Konstanze Hörtnagel; Ute Thyen; Jens Volkmann
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

6.  Pyruvate dehydrogenase deficiency presenting as dystonia in childhood.

Authors:  R A Head; C G E L de Goede; R W N Newton; J H Walter; M A McShane; R M Brown; G K Brown
Journal:  Dev Med Child Neurol       Date:  2004-10       Impact factor: 5.449

7.  Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: an open-label study.

Authors:  Laura Cif; Xavier Vasques; Victoria Gonzalez; Patrice Ravel; Brigitte Biolsi; Gwenaelle Collod-Beroud; Sylvie Tuffery-Giraud; Hassan Elfertit; Mireille Claustres; Philippe Coubes
Journal:  Mov Disord       Date:  2010-02-15       Impact factor: 10.338

8.  Intraventricular baclofen for dystonia: techniques and outcomes. Clinical article.

Authors:  A Leland Albright; Susan S Ferson
Journal:  J Neurosurg Pediatr       Date:  2009-01       Impact factor: 2.375

9.  A case of secondary dystonia responding to levodopa.

Authors:  Geneviève Bernard; Michel Vanasse; Sylvain Chouinard
Journal:  J Child Neurol       Date:  2009-10-06       Impact factor: 1.987

10.  Factors predicting improvement in primary generalized dystonia treated by pallidal deep brain stimulation.

Authors:  Xavier Vasques; Laura Cif; Victoria Gonzalez; Claire Nicholson; Philippe Coubes
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

View more
  4 in total

Review 1.  Lesch-Nyhan Syndrome: Models, Theories, and Therapies.

Authors:  Scott Bell; Ilaria Kolobova; Liam Crapper; Carl Ernst
Journal:  Mol Syndromol       Date:  2016-09-24

2.  Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.

Authors:  Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2017-08-20       Impact factor: 4.797

3.  Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.

Authors:  Rebecca Ahrens-Nicklas; Lars Schlotawa; Andrea Ballabio; Nicola Brunetti-Pierri; Mauricio De Castro; Thomas Dierks; Florian Eichler; Can Ficicioglu; Alan Finglas; Jutta Gaertner; Brian Kirmse; Joerg Klepper; Marcus Lee; Amber Olsen; Giancarlo Parenti; Arastoo Vossough; Adeline Vanderver; Laura A Adang
Journal:  Mol Genet Metab       Date:  2018-01-31       Impact factor: 4.797

4.  Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years.

Authors:  Maria G Motlagh; Megan E Smith; Angeli Landeros-Weisenberger; Andrew J Kobets; Robert A King; Joan Miravite; Alain C J de Lotbinière; Ron L Alterman; Alon Y Mogilner; Michael H Pourfar; Michael S Okun; James F Leckman
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-11-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.